

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Sinclair IS Pharma plc				
2 Reason for the notification (please tick the appropriate box or boxes):						
An acquisition or disposal of voting rights					X	
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached						
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments						
An event changing the breakdown of voting rights						
Other (please specify):						
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ		Abingworth LLP Abingworth Bioventures V LP Abingworth Bioequities Master Fund Limited				
4. Full name of shareholder(s) (if different from 3.): ^{iv}		Bank of New York (Nominees) Limited (as nominee for Abingworth Bioventures V LP) Jefferies & Co Inc. (as nominee for Abingworth Bioequities Master Fund Limited)				
5. Date of the transaction and date on which the threshold is crossed or reached: ^v		23 May 2011				
6. Date on which issuer notified:		2 June 2011				
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}		Above 5% - Abingworth Bioventures V LP Above 8% - Abingworth LLP				
8. Notified details: Abingworth Bioventures V LP						
A: Voting rights attached to shares viii, ix						
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction			
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights ^x
			Direct	Direct ^{xi}	Indirect ^{xii}	

Sinclair Pharma plc GB0033856740 1p Ords	9,214,459	9,214,459	22,573,542	22,573,542		5.93%	
--	-----------	-----------	------------	------------	--	-------	--

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date ^{xiii}	Exercise/ Conversion Period ^{xiv}	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial instrument	Exercise price	Expiration date ^{xvii}	Exercise/ Conversion period ^{xviii}	Number of voting rights instrument refers to	% of voting rights ^{xix, xx}	
					Nominal	Delta

Total (A+B+C)

Number of voting rights	Percentage of voting rights
22,573,542	5.93%

8. Notified details: Abingworth LLP

A: Voting rights attached to shares ^{viii, ix}

Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction				
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights ^x	
			Direct	Direct ^{xi}	Indirect ^{xii}	Direct	Indirect
Sinclair Pharma plc GB0033856740 1p Ords		12,880,794			33,433,227		8.78%

B: Qualifying Financial Instruments**Resulting situation after the triggering transaction**

Type of financial instrument	Expiration date ^{xiii}	Exercise/ Conversion Period ^{xiv}	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}**Resulting situation after the triggering transaction**

Type of financial instrument	Exercise price	Expiration date ^{xvii}	Exercise/ Conversion period ^{xviii}	Number of voting rights instrument refers to	% of voting rights ^{xix, xx}	
					Nominal	Delta

Total (A+B+C)

Number of voting rights	Percentage of voting rights
33,433,227	8.78%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^{xxi}

Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both managed by Abingworth LLP.

Proxy Voting:

10. Name of the proxy holder:	
11. Number of voting rights proxy holder will cease to hold:	

12. Date on which proxy holder will cease to hold voting rights:	
---	--

13. Additional information:	
------------------------------------	--

14. Contact name:	John Heard
--------------------------	------------

15. Contact telephone number:	0207 534 1508
--------------------------------------	---------------